Stayble Therapeutics has strengthened its scientific advisory board (SAB) with two knowledgeable and reputable members - Dr Aaron Calodney and Dr Douglas Beall. They will contribute their knowledge and experience within pain management and spine-related issues as well as bring an important US perspective. BioStock contacted the company's Chief Scientific Officer (CSO) Anders Lehmann regarding the new recruits.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se